Quidel Corp is a corporation, originally incorporated as Monoclonal Antibodies, Inc. in California in 1979 and re-incorporated as Quidel Corporation in the State of Delaware in 1987. The Company is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions include applications in infectious diseases, women's health and gastrointestinal diseases. It sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and through a direct sales force. Internationally, it markets through distributor arrangements. The Company commenced its operations in 1979 and launched its first products, dipstick-based pregnancy tests, in 1983. In February 2010, it expanded its operations through the acquisition of Diagnostic Hybrids, Inc., a privately-held, in vitro diagnostics (IVD) company, based in Athens, Ohio. In 2013, it completed two further acquisitions, acquiring BioHelix Corporation, a developer and manufacturer of isothermal molecular assays and enzymes, in May 2013, and acquiring the assets of AnDiaTec GmbH, a German based developer and manufacturer of molecular assays, in August 2013. The Company's customers for IVD products are centralized laboratories and physician offices and decentralized point-of-care settings. It provides diagnostic testing solutions under various brand names, including, among others, - Quidel, QuickVue, QuickVue+, Sofia, AmpliVue, Solana, Virena, MicroVue, Lyra, FreshCells, D3, FastPoint, ReadyCells, Super E-Mix, ELVIRA, ELVIS and Thyretain. The diagnostic testing solutions are provided through a number of proprietary platforms, including Fluorescent Immunoassays; Molecular Assays; Molecular Systems in Development; and Connectivity and Data Management. The products under medical and wellness categories are Infectious Diseases - Influenza, Streptococci, RSV, Multiplex Respiratory, General Virology, Herpes and Herpes Family; POC Women's and General Health - Pregnancy, Graves Disease, Chlamydia, Bone Health; Bone Health, Autoimmune Disease and Oncology; Gastrointestinal Diseases - Clostridium difficile, Enterovirus, Helicobacter pylori, Immunoassay fecal occult blood. The Company has two manufacturing sites in San Diego, California and Athens, Ohio. San Diego facility consists of laboratories devoted to tissue culture, cell culture, protein purification and immunochemistry and production areas dedicated to manufacturing and assembly. Athens facility consists of clean rooms (FS-209E Class 1000: ISO Class 6) for the culturing and dispensing of cell cultures under cGMP conditions. The facility also has laboratories devoted to tissue culture for the production of monoclonal antibodies. The Company's competitors include, among others, Alere Inc., Beckman Coulter Primary Care Diagnostics, Fisher Scientific Corporation, Becton Dickinson and Company, Meridian Bioscience, Inc., Cepheid Inc. and Chemicon International, Inc.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.